# Safety Evaluation of Intranasal Use of DSM 32444 Postbiotic in Humans

> **NCT05984004** · NA · COMPLETED · sponsor: **Huro Biotech Joint Stock Company** · enrollment: 60 (actual)

## Conditions studied

- Rhino Sinusitis

## Interventions

- **DRUG:** 0.9% NaCl isotonic saline solution
- **COMBINATION_PRODUCT:** Bacillus subtilis DSM32444, inactivated

## Key facts

- **NCT ID:** NCT05984004
- **Lead sponsor:** Huro Biotech Joint Stock Company
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-26
- **Primary completion:** 2022-11-22
- **Final completion:** 2023-04-20
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05984004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05984004, "Safety Evaluation of Intranasal Use of DSM 32444 Postbiotic in Humans". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05984004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*